PipelineReview.com6h
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)
SHANGHAI, China I5, 2025 I YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of ...
PipelineReview.com6h
CancerVax Announces Successful Tests of its Smart mRNA Technology
Recent in-vitro lab results confirm that the Company’s proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells ...
PipelineReview.com23h
LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301
REDWOOD CITY, CA, USA & SHENZHEN, China I4, 2025 I LTZ Therapeutics, an immunotherapy-focused biotech company, today announced that the U.S.
PipelineReview.com23h
Vicero’s Novel Cancer Immunotherapy Demonstrates Dual-Target Precision with Improved Safety Profile
Late-breaker poster presentation at the inaugural AACR IO underscores potential of VCR-036, a novel PD-1/CTLA-4 VHH antibody for treatment of solid tumors ...